Cited by 300Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice

Open access

McConlogue, Lisa, Buttini, Manuel, Anderson, John P., Brigham, Elizabeth F., Chen, Karen S., Freedman, Stephen B., Games, Dora, Johnson-Wood, Kelly, Lee, Michael, Zeller, Michelle, Liu, Weiqun, Motter, Ruth, Sinha, Sukanto·2007·Journal of Biological Chemistry

DOI 10.1074/jbc.m611687200

Open this paper in CoChat — free account

Abstract

The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta (Abeta) peptide, the major component of Alzheimer disease (AD) plaques. To determine the role that BACE1 plays in the development of Abeta-driven AD-like pathology, we have crossed PDAPP mice, a transgenic mouse model of AD overexpressing human mutated APP, onto mice with either a homozygous or heterozygous BACE1 gene knockout. Analysis of PDAPP/BACE(-/-) mice demonstrated that BACE1 is absolutely required for both Abeta generation and the development of age-associated plaque pathology. Furthermore, synaptic deficits, a neurodegenerative pathology characteristic of AD, were also reversed in the bigenic mice. To determine the extent of BACE1 reduction required to significantly inhibit pathology, PDAPP mice having a heterozygous BACE1 gene knock-out were evaluated for Abeta generation and for the development of pathology. Although the 50% reduction in BACE1 enzyme levels caused only a 12% decrease in Abeta levels in young mice, it nonetheless resulted in a dramatic reduction in Abeta plaques, neuritic burden, and synaptic deficits in older mice. Quantitative analyses indicate that brain Abeta levels in young APP transgenic mice are not the sole determinant for the changes in plaque pathology mediated by reduced BACE1. These observations demonstrate that partial reductions of BACE1 enzyme activity and concomitant Abeta leve…

Integrity signals

Registry

Crossref · 10.1074/jbc.m611687200

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Self-citation
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citation
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Self-citation
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123
Self-citation
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703
Aβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 359

Flagged first, then by citations

Show all 13 references

Research works printed but not linked: 44

Selkoe, 2001, Physiol. Rev., 81, 741, 10.1152/physrev.2001.81.2.741 · DOI · Paper page
Selkoe, 2003, Annu. Rev. Pharmacol. Toxicol., 43, 545, 10.1146/annurev.pharmtox.43.100901.140248 · DOI
Sinha, 1999, Nature, 402, 537, 10.1038/990114 · DOI · Paper page
Yan, 1999, Nature, 402, 533, 10.1038/990107 · DOI · Paper page
Roberds, 2001, Hum. Mol. Genet., 10, 1317, 10.1093/hmg/10.12.1317 · DOI · Paper page
Cai, 2001, Nat. Neurosci., 4, 233, 10.1038/85064 · DOI
Luo, 2001, Nat. Neurosci., 4, 231, 10.1038/85059 · DOI · Paper page
Luo, 2003, Neurobiol. Dis., 14, 81, 10.1016/S0969-9961(03)00104-9 · DOI
Laird, 2005, J. Neurosci., 25, 11693, 10.1523/JNEUROSCI.2766-05.2005 · DOI · Paper page
Dominguez, 2005, J. Biol. Chem., 280, 30797, 10.1074/jbc.M505249200 · DOI
Masliah, 1996, J. Neurosci., 16, 5795, 10.1523/JNEUROSCI.16-18-05795.1996 · DOI
Chen, 1998, Prog. Brain Res., 117, 327, 10.1016/S0079-6123(08)64025-X · DOI
Bornemann, 2000, Ann. N. Y. Acad. Sci., 908, 260, 10.1111/j.1749-6632.2000.tb06653.x · DOI
Hsiao, 1996, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
Holcomb, 1998, Nat. Med., 4, 97, 10.1038/nm0198-097 · DOI · Paper page
Ohno, 2004, Neuron, 41, 27, 10.1016/S0896-6273(03)00810-9 · DOI · Paper page
Ohno, 2006, Eur. J. Neurosci., 23, 251, 10.1111/j.1460-9568.2005.04551.x · DOI · Paper page
Mucke, 2000, J. Neurosci., 20, 4050, 10.1523/JNEUROSCI.20-11-04050.2000 · DOI · Paper page
Rockenstein, 1995, J. Biol. Chem., 270, 28257, 10.1074/jbc.270.47.28257 · DOI
Johnson-Wood, 1997, Proc. Natl. Acad. Sci. U. S. A., 94, 1550, 10.1073/pnas.94.4.1550 · DOI
Masliah, 1992, Ann. Neurol., 32, 321, 10.1002/ana.410320304 · DOI
Buttini, 1999, J. Neurosci., 19, 4867, 10.1523/JNEUROSCI.19-12-04867.1999 · DOI
Gruninger-Leitch, 2002, J. Biol. Chem., 277, 4687, 10.1074/jbc.M109266200 · DOI · Paper page
Danner, 2002, Neurobiol. Aging (Abstr. 905), 23, S241
Dickson, 1988, Am J. Pathol., 132, 86
Dickson, 2001, Neuroscience, 105, 99, 10.1016/S0306-4522(01)00169-5 · DOI · Paper page
Grace, 2002, Neuroscience, 114, 265, 10.1016/S0306-4522(02)00241-5 · DOI
Spires, 2004, Rev. Neurosci., 15, 267, 10.1515/REVNEURO.2004.15.4.267 · DOI
Kobayashi, 2007, Neurobiol. Aging, in press
Kitazume, 2001, Proc. Natl. Acad. Sci. U. S. A., 98, 13554, 10.1073/pnas.241509198 · DOI · Paper page
Li, 2004, J. Biol. Chem., 279, 10542, 10.1074/jbc.M310001200 · DOI · Paper page
Kitazume, 2005, J. Biol. Chem., 280, 8589, 10.1074/jbc.M409417200 · DOI · Paper page
Kitazume, 2003, J. Biol. Chem., 278, 14865, 10.1074/jbc.M206262200 · DOI
Lichtenthaler, 2003, J. Biol. Chem., 278, 48713, 10.1074/jbc.M303861200 · DOI · Paper page
Rabe, 2006, The International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain, July 15–20, 2006, Abstracts P3–259, Medimond, Bologna, Italy
Kamenetz, 2003, Neuron, 37, 925, 10.1016/S0896-6273(03)00124-7 · DOI · Paper page
Cohen, 2003, Nature, 426, 905, 10.1038/nature02265 · DOI
Terry, 1991, Ann. Neurol., 30, 572, 10.1002/ana.410300410 · DOI · Paper page
Buttini, 2005, J. Neurosci., 25, 9096, 10.1523/JNEUROSCI.1697-05.2005 · DOI · Paper page
Mucke, 1996, Ann. N. Y. Acad. Sci., 777, 82, 10.1111/j.1749-6632.1996.tb34405.x · DOI
Lue, 1999, Am. J. Pathol., 155, 853, 10.1016/S0002-9440(10)65184-X · DOI · Paper page
McLean, 1999, Ann. Neurol., 46, 860, 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · DOI
McPhie, 2001, Brain Res. Mol. Brain Res., 97, 103, 10.1016/S0169-328X(01)00294-7 · DOI
Shi, 2005, J. Alzheimers Dis., 7, 139, 10.3233/JAD-2005-7207 · DOI

Sorted by citations

Items 201–269 of 269

The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
Dekeryte, R., Franklin, Z., Hull, C., Croce, L., Kamli-Salino, S., Helk, O., Hoffmann, P. A., Yang, Z.-X., Riedel, G., Delibegović, M., et al. (2021) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166149 · Cited by 17
“23 inhibition would lead to ~20% decrease in brain Aβ [28,29].”
Background
Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors
Coimbra, J. R. M., Baptista, S. J., Dinis, T., Silva, M. C., Moreira, P., Santos, A., & Salvador, J. A. R. (2020) · Biomolecules · doi:10.3390/biom10040535 · Cited by 17
“Fortunately, studies suggest that partial inhibition of BACE1 activity might be enough to prevent amyloid pathology and reduce the risk of developing AD [19].”
Background
Impact of the Cannabinoid System in Alzheimer's Disease
Li, S., Huang, Y., Yu, L., Ji, X., & Wu, J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201091006 · Cited by 28
“Then insoluble Aβ fibrils form oligomers, diffuse into the synaptic cleft, and interfere with synaptic signaling [6-8].”
Identification of ovalbumin-derived peptides as multi-target inhibitors of AChE, BChE and BACE1.
Yu, Z.-P., Dong, W., Wu, S.-J., Shen, J., Zhao, W.-Z., Ding, L., Liu, J.-B., & Zheng, F.-P. (2020) · The Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.10295 · Cited by 16
Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice
Dong, W., Wang, F., Chen, Y., Zheng, X.-H., Xie, Y.-C., Guo, W., & Shi, H. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00148 · Cited by 16
“Lowering BACE1 expression reduced the formation of Aβ, thereby preventing its subsequent aggregation into toxic aggregates (Citron, 2002; McConlogue et al., 2007).”
BackgroundResult
Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40and Aβ42following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers
Quartino, A. L., Huledal, G., Sparve, E., Lüttgen, M., Bueters, T., Karlsson, P., Olsson, T., Paraskos, J., Maltby, J., Claeson‐Bohnstedt, K., et al. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.130 · Cited by 17
“In BACE1 heterozygous knockout mice, a 12% decrease in soluble Ab levels at early age resulted in a dramatic reduction of Ab plaques, neuritic burden, and synaptic deficits at an older age.(33) Also, an average 20–25% lowering of central Ab levels with a g-secretase inhibitor attenuated progression of amyloid plaque i…”
Background
Camelid heavy chain only antibody fragment domain against β‐site of amyloid precursor protein cleaving enzyme 1 inhibits β‐secretase activity in vitro and in vivo
Dorresteijn, B., Rotman, M., Faber, D., Schravesande, R., Suidgeest, E., van der Weerd, L., van der Maarel, S. M., Verrips, C. T., & Khattabi, M. E. (2015) · FEBS Journal · doi:10.1111/febs.13367 · Cited by 15
Fangchinoline alleviates cognitive impairments through enhancing autophagy and mitigating oxidative stress in Alzheimer’s disease models
Yi, L., Luo, M., Wang, M., Dong, Z., & Du, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1288506 · Cited by 15
A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease
Mycroft-West, C. J., Cooper, L. C., Devlin, A., Procter, P., Guimond, S., Guerrini, M., Fernig, D., Lima, M., Yates, E., & Skidmore, M. (2019) · bioRxiv · doi:10.3390/md17050293 · Cited by 14
BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains
Čaušević, M., Dominko, K., Malnar, M., Vidatic, L., Čermak, S., Pigoni, M., Kuhn, P., Colombo, A. V., Havas, D., Flunkert, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200344 · Cited by 20
“cleaved by BACE1 [32], together with studies on AD-transgenic mice crossed with genetically deleted BACE1 mice, showing a decrease in Aβ levels and protection against AD and cognitive decline [33, 34, 35, 36, 37], strongly suggest that BACE1-inhibition should prove effective for AD treatment.”
Background
Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE.
Wu, Y.-J., Zhang, Y.-H., Good, A., Burton, C., Toyn, J., Albright, C., Macor, J., & Thompson, L. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.144 · Cited by 14
Putative pathological mechanisms of late-life depression and Alzheimer’s disease
Hasan, S. M. N., Clarke, C., Strand, T., & Bambico, F. R. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148423 · Cited by 13
Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig
Janson, J., Eketjäll, S., Tunblad, K., Jeppsson, F., Berg, S., Niva, C., Radesater, A.-C., Fälting, J., & Visser, S. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1189-y · Cited by 13
Membrane Anchored and Lipid Raft Targeted β-Secretase Inhibitors for Alzheimer's Disease Therapy
Halima, S. B., & Rajendran, L. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110269 · Cited by 22
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo.
Hirata‐Fukae, C., Sidahmed, E., Gooskens, T. P., Aisen, P., Dewachter, I., Devijver, H., Leuven, F. V., & Matsuoka, Y. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.032 · Cited by 13
“Endogenous Abeta levels were unchanged in BACE1(+/−) mice compared to BACE1(+/+) mice [13] and Abeta reduction was minimal (∼12%) and not statistically significant reduced in BACE(+/−)/APP mice at 3 months of age [ 12 ].”
New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer’s Disease Models
Resende, R., Ferreira‐Marques, M., Moreira, P., Coimbra, J. R. M., Baptista, S. J., Isidoro, C., Salvador, J. A. R., Dinis, T. C. P., Pereira, C., & Santos, A. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200381 · Cited by 17
“Of note, our aim was to inhibit only a small percentage of A (cid:2) production since it is known from the literature that this translates into a considerably greater effect on insoluble A (cid:2) levels upon chronic administration [15].”
Influential
BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
Decourt, B., Gonzales, A., Beach, T. G., Malek‐Ahmadi, M. H., Walker, A. W., Sue, L. I., Walker, D. G., & Sabbagh, M. N. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030010 · Cited by 11
“Recent evidence from transgenic animal and in vitro studies suggests that beta-site APP-cleaving enzyme 1 (BACE1) is the major β-secretase in the brain [4, 5] and the rate-limiting enzyme in amyloidogenesis [6, 7].”
Background
Expression analysis of human β-secretase in transgenic tomato fruits.
Kim, H. S., Youm, J., Moon, K.-B., Jang, H.-H., Kim, Y. H., Joung, H., & Jeon, J. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2011.11.012 · Cited by 12
“These highly insoluble, plastic-like deposits are composed of a 4-kDa b-amyloid protein (Ab) derived from the amyloid precursor protein (APP) by sequential proteolysis of b-secretase and c-secretase [1,2].”
Background
Promoter polymorphisms which modulate BACE1 expression are associated with sporadic Alzheimer's disease
Wang, S., & Jia, J. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30968 · Cited by 12
“BACE1 knockout mice, without developmental deficits, have abolished Ab generation [McConlogue et al., 2007].”
Background
Activation of peroxisome proliferator‐activated receptor delta suppresses BACE 1 expression by up‐regulating SOCS 1 in a JAK 2/ STAT 1‐dependent manner
Lee, W. J., Ham, S. A., Lee, G. H., Choi, M., Yoo, H., Paek, K. S., Lim, D., Hong, K., Hwang, J. S., & Seo, H. G. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14715 · Cited by 13
RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation
Dong, Y.-L., Xu, Z.-P., Zhang, Y.-Y., McAuliffe, S., Wang, H., Shen, X., Yue, Y., & Xie, Z.-C. (2011) · Medical Gas Research · doi:10.1186/2045-9912-1-5 · Cited by 11
“Previous in vivo studies have shown that a 50% reduction in BACE1 levels causes only a 12% decrease in Ab levels in heterozygous BACE1 gene knock-out mice [77].”
Background
The amyloid-β peptide: Guilty as charged?
Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 12
Dengzhan shengmai capsule combined with donepezil hydrochloride in the treatment of Alzheimer's disease: preliminary findings, randomized and controlled clinical trial.
Huang, P., He, X.-Y., & Xu, M. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.67.02.20200378 · Cited by 10
A Peptide Binding to the β-Site of APP Improves Spatial Memory and Attenuates Aβ Burden in Alzheimer’s Disease Transgenic Mice
Yang, S.-G., Wang, S.-W., Zhao, M., Zhang, R., Zhou, W.-W., Li, Y.-N., Su, Y.-J., Zhang, H., Yu, X.-L., & Liu, R.-T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048540 · Cited by 10
[3H]BMS-599240--a novel tritiated ligand for the characterization of BACE1 inhibitors.
Iben, L., Kopcho, L., Marcinkeviciene, J., Zheng, C.-S., Thompson, L., Albright, C., & Toyn, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.112 · Cited by 9
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 9
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors.
Bertini, S., Ghilardi, E., Asso, V., Minutolo, F., Rapposelli, S., Digiacomo, M., Saccomanni, G., Salmaso, V., Sturlese, M., Moro, S., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.058 · Cited by 8
Alzheimer’s Disease and Animal Models in Retrospect
Fajemiroye, J. O. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000215 · Cited by 6
Silencing of Amyloid Precursor Protein Expression Using a New Engineered Delta Ribozyme
Aissa, M. B., April, M.-C., Bergeron, L. J., Perreault, J., & Lévesque, G. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/947147 · Cited by 5
“Because only a 12% decrease in Aβ levels in mice resulted in a dramatic reduction in Aβ build-up and synaptic deficits [49], we are optimistic that the results obtained in our cellular model will allow for the development of an efficacious form of SOFA-HDV ribozyme-based therapy.”
Phytochemical Interactions with Calmodulin and Critical Calmodulin Binding Proteins Involved in Amyloidogenesis in Alzheimer’s Disease
O’Day, D. H. (2023) · Biomolecules · doi:10.3390/biom13040678 · Cited by 8
“As a result, due to these many roles the complete removal of the enzyme using gene knockouts or the complete inhibition of enzyme activity has led to neurological and other defects [48,49].”
Background
Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study
Tian, S., Huang, R., Guo, D., Lin, H., Wang, J., An, K., & Wang, S. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200522210957 · Cited by 7
Synthesis and evaluation of 11C-labeled naphthalene derivative as a novel non-peptidergic probe for the β-secretase (BACE1) imaging in Alzheimer's disease brain.
Kawai, T., Kawashima, H., Kuge, Y., & Saji, H. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.03.008 · Cited by 7
“Because Aβ constitute senile plaque, which is one of the major pathological changes in Alzheimer's disease (AD) brain, it is considered that BACE1 plays an important role in the development of AD [1–3].”
Background
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5
“The research of drugs inhibiting BACE1 activity was encouraged by studies revealing that the expression of mutated BACE1 reduces amyloidogenesis and cognitive impairment in APP transgenic mice [9, 10].”
Nuclear factor kappa B (NF-κB) participates in the aluminum-induced down-regulation of miR29a/b1
Wang, L., Zhang, J., Zhao, Y., Li, J., Lu, X., Song, J., Zhang, L., & Niu, Q. L. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127309 · Cited by 6
Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application
Yang, J., Jia, L., Li, Y., Qiu, Q., Quan, M., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201068 · Cited by 4
“Work in animal models indicates that even partial reduction of A (cid:2) 42 concentration in CSF is associated with a substantial lowering of amyloid plaque formation and growth [78, 79].”
AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer’s disease mouse modelPreprint
Rincón, M. Y., Zhou, L., Marneffe, C., Voytyuk, I., Wouters, Y., Dewilde, M., Duqué, S. I., Vincke, C., Levites, Y., Golde, T. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/698506 · Cited by 7
“…a reduction of 50% in the levels of BACE1 activity is sufficient to significantly reduce Aβ plaques, neuritic burden, and synaptic deficits in mouse models of AD (McConlogue et al, 2007), similar to the effects seen with a reduction of 30% in the levels of gamma secretase activity (Li et al, 2007).”
Background
Development of a Novel β-Secretase Binding Assay Using the AlphaScreen Platform
Ren, Z., Tam, D., Xu, Y., Wone, D. W. G., Yuan, S., Sham, H. L., Cheung, H., Regnström, K. J., Chen, X., Rudolph, D., et al. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113482138 · Cited by 7
TNIP2 inhibits amyloidogenesis by regulating the 3′UTR of BACE1: An in vitro study
Chen, L., Wang, L., Zhou, G., Liu, Y., Chen, X., Xie, X., Wen, Q., Li, C., Yang, J., & Chen, G. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137265 · Cited by 6
Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.
Campagna, J. J., Vadivel, K., Jagodzinska, B., Jun, M., Bilousova, T. V., Spilman, P., & John, V. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.002 · Cited by 5
Qualification and application of a liquid chromatography–tandem mass spectrometric method for the determination of human Aβ1-40 and Aβ1-42 peptides in transgenic mouse plasma using micro-elution solid phase extraction
Shin, Y., Hamm, L., Murakami, S., Buirst, K., Buonarati, M., Cox, A. A., Regal, K., Hunt, K. W., Scearce-Levie, K., Watts, R., et al. (2013) · Archives of pharmacal research · doi:10.1007/s12272-013-0215-2 · Cited by 5
“Importantly, hAPP transgenic mice that are heterozygous for BACE1 knockout show a dramatic reduction in amyloid plaques and protection against synaptic and cognitive deficits (Laird et al. 2005; McConlogue et al. 2007; Ohno et al. 2004).”
Background
Methodological Issues : Do Membrane Rafts Exist ?
Gulati, V., & Wallace, R. (2012) · doi:10.4324/9780203104507-16 · Cited by 5
“Investigators suggest that partial inhibition of BACE1 may be required, a strategy perhaps sufficient, to prevent Aβ synthesis [114].”
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
β-Secretase Inhibition
Vassar, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00003-4 · Cited by 3
Dysregulation of Long Non-coding RNAs in Human Disease
Lin, N., & Rana, T. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8621-3_5 · Cited by 5
Partial, Rather than Full, BACE1 Inhibition May Be a Better Therapeutic Strategy for Alzheimer’s Disease Due to Effects of Complete Loss of BACE1 Activity on Adult Hippocampal Neurogenesis
Carney, R. S. E. (2018) · eNeuro · doi:10.1523/eneuro.0384-18.2018 · Cited by 3
“Supporting this approach is the observation that transgenic models of AD do not exhibit amyloid pathology when crossed with mice deficient in BACE1 (Luo et al., 2003; Laird et al., 2005; McConlogue et al., 2007; Ohno et al., 2007).”
Background
Effects of Newly Synthesized Recombinant Human Amyloid-β Complexes and Poly-Amyloid-β Fibers on Cell Apoptosis and Cognitive Decline.
Park, S., Huh, J., Eom, T., Na, N., Lee, Y., Kim, J.-S., Kim, S.-U., Shim, I., Lee, S.-R., & Kim, E. (2017) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1707.07003 · Cited by 3
“Moreover, AD does not develop from a single gene abnormality, but from double gene modification due to co-factors such as BACE, apolipoprotein E, and presenilin [22-26].”
Background
Emerging role of G-quadruplexes in alternative splicing regulation
Peynet, A., Sénéchal, R. L., Keruzoré, M., Lejault, P., Quillévéré, A., Loaëc, N., Martin, N. G., Lepan, T., Teulade‐Fichou, M., Corcos, L., et al. (2026) · Trends in Genetics · doi:10.1016/j.tig.2026.05.001 · Cited by 2
Effect of Functional Inhibition of BACE1 on Sensitization to γ-Irradiation in Cancer Cells
Nakamoto, K., Kikuhara, S., Fujimori, H., Saraswat, B., Gao, Z., Velu, A. V., Zhang, Z., Tong, Y., Imamichi, S., Nozaki, T., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46010028 · Cited by 2
“BACE1 knockout mice have been produced but showed no apparent phenotypes, suggesting that BACE1 inhibition will not cause severe side effects [13–15].”
Background
Frontiers in Clinical Drug Research - Alzheimer Disorders
Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1
BACE: A (Almost) Perfect Target for Staving off Alzheimer's Disease
Sinha, S. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527630943.ch14 · Cited by 1
Self-citation
Organofluorine Compounds in Neurological Disorders
Reddy, V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53748-5.00008-3 · Cited by 2
Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis
Lee, H. J., Jung, Y. H., Choi, G. E., Kim, J. S., Chae, C. W., Lim, J. R., Kim, S. Y., Yoon, J. H., Cho, J. H., Lee, S., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0593-1 · Cited by 180
Assessment of neuroprotective effects of gamma-hydroxybutyrate and neurosteroids on cellular models of Alzheimer’s disease
Wendt, G. (2014) · doi:10.22028/d291-23005 · Cited by 1
“&0%'&%' various APP-overexpressing mouse models (Laird et al., 2005, McConlogue et al., 2007, Kobayashi et al., 2008).”
Background
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
van Eersel, J., Delerue, F., Ittner, L. M., & Ke, Y. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_8
Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy
Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2
Role of BACE1 in Cognitive Function, from Alzheimer’s Disease to Traumatic Brain Injury
Lombardo, S., & Tesco, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00008-5 · Cited by 2
Aspartic Proteases of Alzheimer’s Disease: β- and γ-Secretases
Wolfe, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10077-x · Cited by 2
Modulation of BACE1 Activity as a Potential Therapeutic Strategy for Treating Alzheimer’s Disease
Klaver, D. W., & Tesco, G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50009-x · Cited by 1
Glycogen synthase kinase-3 signaling in Alzheimer's disease : regulation of beta-amyloid precursor protein processing and amyloid beta protein production
Ly, P. (2012) · cIRcle (University of British Columbia) · doi:10.14288/1.0072944 · Cited by 1
“In fact, even a partial reduction of BACE1 can have dramatically beneficial effects on AD pathology (McConlogue et al., 2007), suggesting that inhibition of BACE1 is a valid therapeutic target for AD treatment.”
Disturbed Spatial Learning and Hippocampal Molecular and Histological Alterations in Middle-Aged Rats with a History of Polycystic Ovary Syndrome
Noroozzadeh, M., Changaei, M., Farhadi-Azar, M., Mousavi, M., Mousapour, P., Amiri, M., Jorjani, M., & Tehrani, F. R. (2026) · International Journal of Endocrinology and Metabolism · doi:10.5812/ijem-167083
Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease
Campagna, J. J., Jagodzinska, B. M., Wi, D., Zhu, C., Lee, J. L., Cohn, W., Jun, M., Elias, C. J., Padder, S., Descamps, O., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00610 · Cited by 10
“Such a partial BACE1 inhibition therapeutic approach is supported by the previous ﬁ nding of McConlogue et al. [38] that indicated, at least in a mouse model of AD, that only a 12 % decrease in A β levels in brain results in dramatic reduction in plaque pathology.”
Synthesis of a carbon-11 radiolabeled BACE1 inhibitor
Zhu, Y., Fiedler, S. A., Hibert, M., & Wang, C. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02480-9
Therapies Aimed at Controlling Gene Expression, Including up‐Regulating a Chaperone or down‐Regulating an Amyloidogenic Protein
Lotz, G. P., & Muchowski, P. J. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch44
Implications of alpha- and beta-secretase expression and function in Alzheimer's disease
Reinhardt, S., & Endres, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00016-5
Regulation of IAPP transcription by spliced XBP1
Lin, S. (2019) · doi:10.14288/1.0376219
“Various in vivo studies have shown that full or partial genetic ablation of BACE1 in APP transgenic mouse models can reduce Aβ burden and rescue Aβ-induced memory deficits (Laird et al., 2005; McConlogue et al., 2007; Ohno et al., 2004), further cementing the importance of BACE1 in AD pathogenesis.”
Background
Die Rolle der neuronalen p38α Mitogen-aktivierten Proteinkinase in der Alzheimer-Krankheit
Schnöder, L. (2017) · doi:10.22028/d291-27214
“Studien an BACE knock-out (ko) Mäusen (Luo, 2003; Ohno et al., 2004; Laird et al., 2005; Ohno et al., 2006; Mcconlogue et al., 2007; Ohno et al., 2007; May et al., 2011) oder Applikation von BACE Inhibitoren (Filser et al., 2015) verringern den zerebralen Aβ-Gehalt und beheben Defizite in…”
BackgroundInfluential
Verubecestat
Stamford, A. W., Cumming, J. N., Scott, J. D., & Strickland, C. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12453-9 · Cited by 1
BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease
Decourt, B., Macias, M. P., Sabbagh, M. N., & Adem, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50010-6
The effect of high glucose on APP metabolism and Abeta production
Yang, Y. (2013) · Joint Conference of the Information Retrieval Communities in Europe · doi:10.14288/1.0073763
“In addition, 50% reduction in BACE1 activity resulted in a remarkable reduction in Aβ plaques and synaptic deficits (McConlogue et al., 2007).”

Authors: McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., Liu, W., Motter, R., & Sinha, S.
Affiliations: Elan Pharmaceuticals, Inc. (Ireland) (IE)
Corresponding author: McConlogue, Lisa
ORCID: McConlogue, Lisa
Buttini, Manuel
Chen, Karen S.
Freedman, Stephen B.
Lee, Michael
Zeller, Michelle
Liu, Weiqun
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 2007-09
Volume: 282
Issue: 36
Pages: 26326-26334
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1074/jbc.m611687200
OpenAlex: W2000536660
Cited by: 300
References: 56
Citations by year: 2026: 4 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 8 · 2020: 18 · 2019: 16 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 24 · 2014: 24 · 2013: 17 · 2012: 23
FWCI: 14.91
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 4774 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: BACE1, Alzheimer's disease, amyloid-beta, amyloid plaques, APP transgenic mice, PDAPP mice, synaptic deficits, neuritic plaques, therapeutic target
MeSH terms: Aging, Alzheimer Disease, Animals, Disease Models, Animal, Enzyme Activation, Humans, Synaptic Membranes, Aspartic Acid Endopeptidases, Neurites, Amyloid beta-Protein Precursor, Mice, Knockout, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks